Keith Katkin - 23 May 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
Director
Signature
/s/ Richard S. Lindahl, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
23 May 2025
Net transactions value
-$49,417
Form type
4
Filing time
28 May 2025, 16:08:23 UTC
Previous filing
19 May 2025
Next filing
16 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Katkin Keith Director 300 PROFESSIONAL DRIVE, GAITHERSBURG /s/ Richard S. Lindahl, Attorney-in-fact 28 May 2025 0001314596

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Sale $49,417 -7,844 -8.3% $6.30 86,431 23 May 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated November 8, 2024, for the purpose of satisfying tax obligations relating to the vesting of RSUs on May 22, 2025.
F2 For reporting purposes, sales prices within a $1 range have been aggregated and the weighted average sales price has been reported. The price ranges were: $6.22 - $6.35. The Company maintains a record of the transactions and copies will be provided upon request.